•
AP
APGE
Apogee Therapeutics, Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
5.60B
Volume
729.67K
52W High
$84.56
52W Low
$26.20
Open
$0.00
Prev Close
$82.04
Day Range
0.00 - 0.00
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Latest News
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
GlobeNewswire Inc.•Jan 6
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
GlobeNewswire Inc.•Nov 10
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
GlobeNewswire Inc.•Oct 10
Why Apogee Therapeutics Stock Triumphed on Thursday
The Motley Fool•Oct 9
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
GlobeNewswire Inc.•Oct 9
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
GlobeNewswire Inc.•Jul 7
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
GlobeNewswire Inc.•Jul 6
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
GlobeNewswire Inc.•May 12